Immunic, Inc. (IMUX)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Jason Tardio M.B.A.
|
COO & President | 751.7k | -- | 1977 |
|
Mr. Glenn Whaley CPA
|
Chief Financial Officer | 682.25k | -- | 1968 |
|
Mr. Erik Lundgren
|
CEO & Director | -- | -- | 1978 |
|
Dr. Hella Kohlhof
|
Co-Founder & Chief Scientific Officer | -- | -- | 1973 |
|
Ms. Jessica Breu
|
Vice President of Investor Relations & Communications | -- | -- | -- |
|
Mr. Inderpal Singh
|
General Counsel | -- | -- | 1966 |
Immunic, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 100
Description
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
November 13, 2026 at 1:30 PM UTC
Immunic, Inc. Earnings Date
